News | December 07, 2025
Biocon to merge Biocon Biologics in $5.5 billion deal
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
The topical fluralaner solution is cleared for the prevention and treatment of new world screwworm infestation
The technology is intended to support imaging-based training, protocol optimisation and surgical planning
The BlueSeal Horizon 3.0T platform incorporates advanced magnet technology
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
The company is excluding data from the affected sites to maintain the study's integrity
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
Suffering from acute migraine? You may soon bid adieu to the debilitating headache
Seeing well-controlled Phase 3 data that shows a marked slowing of lesion growth in Stargardt disease is deeply encouraging
Presbyopia, the age-related loss of near vision, could soon be treated successfully
Subscribe To Our Newsletter & Stay Updated
